Plasma hydroxyproline fractions in patients with dialysis osteodystrophy.
Plasma hydroxyproline fractions were measured in 17 normal subjects and in 54 patients on maintenance haemodialysis therapy (MHT) with various degrees of dialysis osteodystrophy. On the basis of both radiological and histological findings these patients were divided into three groups: radiologically normal, histologically normal and those with osteitis fibrosa. The mean total plasma hydroxyproline concentrations were significantly elevated in all groups of MHT patients. However, these increases were mainly due to peptide-bound and free hydroxyproline fractions. The highest values for these two fractions were found in patients with osteitis fibrosa. The free to peptide-bound hydroxyproline ratio was not significantly altered in the majority of patients on dialysis; the mean ratio was significantly lower in patients with osteitis fibrosa when compared with patients with no histological evidence of bone disease. This finding would suggest that there is no inhibition of hydroxyproline catabolism in patients on haemodialysis and the measurements of both free and peptide-bound hydroxyproline were equally sensitive in identifying patients with osteitis fibrosa.
D001847:Bone Diseases / Q000209:etiology / Q000652:urine*; D006801:Humans; D006909:Hydroxyproline / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000628:therapy; D012016:Reference Values; D006435:Renal Dialysis / Q000009:adverse effects*
D006909:Hydroxyproline